Clinical trial · Interventional
Extensive Staging in Lung Cancer
Randomized Study Comparing Standard Staging of Lung Cancer With Extended Staging Including EBUS-TBNA and PET-MRI
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): due to difficulties with recruiting
Summary
Brief summary (as posted)
The overall aim of this study is to compare standard staging of lung cancer (which includes clinical examination, CT, MRI, bone scan and PET-CT) with comprehensive staging - which includes the new staging methods (PET-MRI and systematic mapping of mediastinal and hilar lymph nodes using endobronchial ultrasound) with respect to disease stage and outcomes of therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET-MRI and EBUS-TBNA | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Standard diagnostic work-up
- description
- All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.
- type
- EXPERIMENTAL
- label
- Extensive diagnostic work-up
- description
- All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).
- interventionNames
- Procedure: PET-MRI and EBUS-TBNA
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- Progression free survival in one year
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
1. Patients undergoing examinations on suspicion of lung cancer (both SCLC and NSCLC) at St. Olavs Hospital 2. Potentially curable disease at the referral time (Stage I-III, based on the first CT) 3. Age ≥ 18 years 4. ECOG Performance 0-2 5. No serious concomitant disorders (for example marked reduced respiratory capacity, active infection, unstable cardiovascular disease, renal dysfunction) that in the opinion of the investigator would compromise the patient's ability to complete the study or interfere with the evaluation of the efficacy and safety of the study procedure 6. No contraindication for study specific procedure - bronchoscopy, CT, MRI and PET. 7. No conditions - medical, social, psychological - which could prevent adequate information and follow-up 8. No pregnancy or lactating women 9. Written informed consent
References
Publications (0)
Data not yet available